Journal of Investigative Medicine最新文献_第2页

Study of role of melanoma-associated antigen D1 (MAGE-D1) in hepatocellular carcinoma. EXPRESS：研究黑色素瘤相关抗原 D1 (MAGE-D1) 在肝细胞癌中的作用。

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2025-01-01 Epub Date: 2024-11-13 DOI: 10.1177/10815589241290195

Muhammad Ibrahim El-Masry

{"title":"Study of role of melanoma-associated antigen D1 (MAGE-D1) in hepatocellular carcinoma.","authors":"Muhammad Ibrahim El-Masry","doi":"10.1177/10815589241290195","DOIUrl":"10.1177/10815589241290195","url":null,"abstract":"Hepatocellular carcinoma (HCC) ranks as the fifth most common neoplasm and the third leading cause of cancer-related deaths worldwide. Current serum biomarkers for HCC surveillance and early diagnosis, particularly alpha-fetoprotein (AFP) the most commonly used marker, lack satisfactory sensitivity and specificity, highlighting an urgent need for more effective markers with higher accuracy for early HCC detection. The downregulation of melanoma-associated antigen D1 (MAGE-D1) transcription plays a crucial role in apoptosis and inhibits cancer cell proliferation when expressed ectopically. Moreover, reduced MAGE-D1 expression correlates with improved prognosis in many cancers. Therefore, this study aims to evaluate the diagnostic role of MAGE-D1 in HCC, proposing it as a novel biomarker for early diagnosis and monitoring of tumor progression. Serum MAGE-D1 expression was measured using RT-qPCR on 198 subjects, divided into three groups: 88 with HCC, 56 with chronic liver conditions, and 54 as healthy controls. With a sensitivity of 93.3% and a specificity of 97.5%, MAGED-1 shows strong potential as a diagnostic marker for HCC. The performance of serum MAGED-1 expression in discrimination between HCC and chronic liver condition revealed an area under the curve (AUC) of 0.939 using the cutoff (0.752) yielded a sensitivity of 90%, specificity of 85%, and an accuracy of 91%. Evaluation of the diagnostic significance of MAGED-1 demonstrated an AUC value of 0.726, with a sensitivity of 63.6% and a specificity of 73.5%. In conclusion, MAGED-1 might be a specific and sensitive biomarker for HCC, potentially improving the malignancy diagnosis and prognosis.","PeriodicalId":16112,"journal":{"name":"Journal of Investigative Medicine","volume":" ","pages":"35-44"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prostate cancer screening: Is it time for a new approach? A review article. 快讯前列腺癌筛查：是时候采用新方法了吗？评论文章。

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2025-01-01 Epub Date: 2024-10-15 DOI: 10.1177/10815589241279414

Christopher James Mikulas, Kabeer Ali, Nirmal Onteddu

引用次数: 0

The scientific value of medical student research: The experience at the Arrow Program for Medical Research Education. 快讯医学生研究的科学价值：医学研究教育箭计划的经验。

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2025-01-01 Epub Date: 2024-11-19 DOI: 10.1177/10815589241280856

Rachel Shemesh, Tamara Wygnanski-Jaffe, Sari David, Tomer Ziv-Baran, Gilad Halpert, Einat Epstain, Eldad Katorza

{"title":"The scientific value of medical student research: The experience at the Arrow Program for Medical Research Education.","authors":"Rachel Shemesh, Tamara Wygnanski-Jaffe, Sari David, Tomer Ziv-Baran, Gilad Halpert, Einat Epstain, Eldad Katorza","doi":"10.1177/10815589241280856","DOIUrl":"10.1177/10815589241280856","url":null,"abstract":"This study presents a comparative analysis of the publications of students participating in the Arrow Research Program in comparison to those of attending physicians and researchers at the same tertiary medical center in order to assess the impact of the Arrow Research Program on the students' scientific achievements. The study encompassed 90 Arrow Research Program students who were involved in the program at the Sheba Medical Center between 2019 and 2021. As a comparison group, 2082 attending physicians and researchers affiliated with the same center during the same period of time were considered. Publications were collected from The Web of Science Database, and the publication data parameters of each group were compared to assess scientific outcomes. The Arrow Research Program students collectively published 67 articles, and the 2082 physicians and researchers in the comparison group produced 4283 papers during the study timeframe. Similarly, the average impact factor of the journals in which the Arrow Research Program papers were published was 4.16 ± 2.68, similar to the average impact factor of 4.74 ± 6.26 in the comparison group (p = 0.388). Likewise, the average quartile of the journals in which the Arrow Research Program articles were published was 1.39 ± 0.59, which is similar to the comparison group's average quartile of 1.39 ± 0.63 (p = 0.997). In conclusion, the Arrow Research Program demonstrates its effectiveness in empowering young students to execute successful research projects. This study may help develop educational programs worldwide.","PeriodicalId":16112,"journal":{"name":"Journal of Investigative Medicine","volume":" ","pages":"147-155"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EXPRESS: Investigation of the synergic effect of mocetinostat and capecitabine in a triple-negative breast neoplasms mouse model.

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2024-12-17 DOI: 10.1177/10815589241309603

Hacer Kaya Çakir, Onur Eroglu

{"title":"EXPRESS: Investigation of the synergic effect of mocetinostat and capecitabine in a triple-negative breast neoplasms mouse model.","authors":"Hacer Kaya Çakir, Onur Eroglu","doi":"10.1177/10815589241309603","DOIUrl":"https://doi.org/10.1177/10815589241309603","url":null,"abstract":"Combined administration of two or more drugs is emerging as a new strategy in triple negative breast neoplasms. This is the first study to investigate the combination of the histone deacetylase inhibitor (HDACi) mocetinostat and the antimetabolite drug capecitabine in triple-negative mammary neoplasms in a preclinical mouse model. 35 female mice were grouped into the control group, capecitabine group, mocetinostat group, and combine drugs group. At the end of experimental period, body weight, tumor weight were measured and tumor tissue and lung tissue were histologically examined. The results showed that the body weight of mice in the drug-treated groups was reduced by about 18%. Tumor weights were also reduced by 21% in the mosetinostat group, 27.5% in the capecitabine group and 45% in the combined group. The combination of mocetinostat and capecitabine decreased the formation of tumors and metastases in lung tissue.In summary, the combination of mocetinostat and capecitabine was more effective than either drug alone in reducing the size of triple-negative breast neoplasms in a mouse model.","PeriodicalId":16112,"journal":{"name":"Journal of Investigative Medicine","volume":" ","pages":"10815589241309603"},"PeriodicalIF":2.5,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EXPRESS: Synergistic Efficacy of Orthokeratology and 0.01% Atropine in Controlling Pediatric Myopia Progression: A Retrospective Analysis.

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2024-12-16 DOI: 10.1177/10815589241308819

Yingying Yang, Zhigang Xiao, Jing Ouyang, Yan Guo

引用次数: 0

EXPRESS: Screening for Presence of Primary Sjogren's Syndrome in Patients with Autoimmune Thyroid Diseases.

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2024-12-16 DOI: 10.1177/10815589241308573

Manar Mohamed Elgebaly, Khaled Shalaby, Hesham Elserougy, Wael Farag, Manal Saad Negm

{"title":"EXPRESS: Screening for Presence of Primary Sjogren's Syndrome in Patients with Autoimmune Thyroid Diseases.","authors":"Manar Mohamed Elgebaly, Khaled Shalaby, Hesham Elserougy, Wael Farag, Manal Saad Negm","doi":"10.1177/10815589241308573","DOIUrl":"https://doi.org/10.1177/10815589241308573","url":null,"abstract":"Autoimmune thyroid disorders (AITD) are the most common autoimmune human disorders as thyroid gland is a main target for autoimmunity. The association between rheumatologic and thyroid disorders has long been known, the most common being the association with rheumatoid arthritis. Our study was conducted to screen for the presence of symptoms, signs and immune markers suggesting presence of Sjogren's syndrome among patients with autoimmune thyroid disorders. Eighty AITD patients (46 patients with Hashimoto's thyroiditis and 34 patients with Graves' disease) were included in the study and forty healthy subjects matched age & sex as a control group. The two groups were compared according to 2002 the American European Consensus Group ( AECG ) criteria for diagnosis of primary Sjogren's syndrome. 12.5% of AITD patients (n=10 patients) were diagnosed as Sjogren's syndrome (AITD-SS). Eight out of ten of AITD-SS had Hashimoto's disease while only two had Grave's disease. Anti Ro was detected in serum of seven patients of the AITD patients with Sjogren syndrome while Anti La was detected in serum of eight patients. The most independent predictors of Sjogren's syndrome in AITD patients are anti La, ESR and salivary gland sonographic change. we conclude that Sjogren's syndrome has been found in patients with AITD and also patients with AITD have symptoms mimic sicca disease despite not fulfill criteria for diagnosis.","PeriodicalId":16112,"journal":{"name":"Journal of Investigative Medicine","volume":" ","pages":"10815589241308573"},"PeriodicalIF":2.5,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142837184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combined treatment with ruxolitinib and MK-2206 inhibits ERα activity by inhibiting MAPK signaling in BT474 breast cancer cells. 表达：Ruxolitinib和MK-2206联合治疗可通过抑制BT474乳腺癌细胞中的MAPK信号转导来抑制ERα活性。

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2024-12-08 DOI: 10.1177/10815589241298184

Esin Guvenir Celik, Onur Eroglu

{"title":"Combined treatment with ruxolitinib and MK-2206 inhibits ERα activity by inhibiting MAPK signaling in BT474 breast cancer cells.","authors":"Esin Guvenir Celik, Onur Eroglu","doi":"10.1177/10815589241298184","DOIUrl":"10.1177/10815589241298184","url":null,"abstract":"Triple-positive breast cancer (TPBC) is a type of breast cancer that overexpresses estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). Dysregulation of ER signaling has been implicated in the pathogenesis of breast cancer. ERα activation triggers the production of second messengers, including cAMP, leading to the activation of signals such as PI3K/AKT or Ras/MAPK. Ruxolitinib is a specific inhibitor of JAK1/JAK2. MK-2206 is an allosteric inhibitor of the Akt. The limitations of the use of ruxolitinib and MK-2206 as single agents necessitate the development of combination therapies with other drugs. This study is the first to investigate the effects of combining ruxolitinib with MK-2206 on MAPK and PI3K/AKT signaling in BT474 breast cancer cells. In addition, this work aimed to increase the anticancer effects of cotreatment with MK-2206 and ruxolitinib. Ruxolitinib, MK-2206, and their combination reduced cell viability in a dose- and time-dependent manner, as determined by MTT assays after 48 h of treatment. Colony formation and wound healing assays demonstrated that MK-2206 exhibited a synergistic anti-proliferative effect. The effects of ruxolitinib, MK-2206, and their combination on PI3K/AKT and MAPK signaling were assessed via western blotting. Ruxolitinib and MK-2206 combined treatment inhibit cell death in BT474 cells by downregulating ERα, Src-1, ERK1/2, SAPK/JNK, and c-Jun. Our results revealed the relationships among the ERα, PI3K/AKT, and MAPK signaling pathways in ER+ breast cancer cells. Understanding the interactions among ERα, PI3K-AKT-mTOR, and MAPK could lead to novel combination therapies.","PeriodicalId":16112,"journal":{"name":"Journal of Investigative Medicine","volume":" ","pages":"10815589241298184"},"PeriodicalIF":2.5,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Normal saline vs balanced intravenous fluids in acute ischemic stroke: A retrospective study. 快讯正常生理盐水与平衡静脉输液在急性缺血性脑卒中中的应用：回顾性研究。

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2024-12-03 DOI: 10.1177/10815589241300081

Joshua J Davis

{"title":"Normal saline vs balanced intravenous fluids in acute ischemic stroke: A retrospective study.","authors":"Joshua J Davis","doi":"10.1177/10815589241300081","DOIUrl":"10.1177/10815589241300081","url":null,"abstract":"While some studies have suggested better outcomes for critically ill patients with balanced solutions over normal saline, the best type of intravenous fluid to use for stroke patients remains unknown. Using a retrospective chart review of 2015-2019 Get with the Guidelines® data at a single academic medical center, this study sought to determine whether balanced solutions or normal saline are associated with risk of hemorrhagic transformation or 90-day disability in patients with acute ischemic stroke treated with intravenous thrombolysis. Exposure was the type of intravenous fluid and outcomes were modified Rankin scale (mRS) ≤2 at 90 days and hemorrhagic transformation. Multivariate analysis controlled for age, demographics, medical history, time to tissue plasminogen activator (tPA), and admission stroke scale. We identified 302 patients who received thrombolysis, of which 166 patients had mRS data at 90 days. In univariate analysis, exposure to any balanced solution was associated with increased 90-day disability (odds ratio (OR) 4.3, 95% confidence interval (CI) 3.8-4.9) and hemorrhagic transformation (OR 2.0, 95% CI 1.3-2.2). In multivariate analysis, exposure to a balanced solution at any time was associated with increased 90-day disability (OR 6.3, 95% CI 2.4-17.0, p < 0.01), but not hemorrhagic transformation. Thus, this observational trial demonstrated that exposure to balanced solutions is associated with an increased risk of disability at 90 days and possibly hemorrhagic transformation in patients with acute ischemic stroke treated with intravenous thrombolysis. This data would suggest that normal saline is a preferred solution in these patients, though larger future trials are needed.","PeriodicalId":16112,"journal":{"name":"Journal of Investigative Medicine","volume":" ","pages":"10815589241300081"},"PeriodicalIF":2.5,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PTBP1 is a potential indicator of disease progression in acute myeloid leukemia. 表达：PTBP1是急性髓性白血病疾病进展的潜在指标。

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2024-12-01 Epub Date: 2024-08-19 DOI: 10.1177/10815589241264783

Lina Xing, Xuefei Guo, Xiaolei Zhang, Ying Wang, Feng He, Jinhai Ren

{"title":"PTBP1 is a potential indicator of disease progression in acute myeloid leukemia.","authors":"Lina Xing, Xuefei Guo, Xiaolei Zhang, Ying Wang, Feng He, Jinhai Ren","doi":"10.1177/10815589241264783","DOIUrl":"10.1177/10815589241264783","url":null,"abstract":"This study aimed to verify a novel potential indicator of disease progression in acute myeloid leukemia (AML) patients. Bone marrow samples were collected from 27 AML patients and 27 controls without hematological malignancies. Polypyrimidine tract-binding protein 1 (PTBP1) expression in bone marrow samples was measured, and the association of PTBP1 with the French-American-British (FAB) classification, cytogenetics, risk stratification, and complete remission (CR) rate was analyzed. The correlation between PTBP1 and Ki-67/p53 expression in AML patients was ultimately evaluated. The results showed that PTBP1 mRNA and protein levels were greater in AML patients than in controls. PTBP1 expression was able to distinguish between AML patients and controls (area under the curve, 0.8601; 95% confidence interval, 0.7632-0.9570). Furthermore, PTBP1 expression was associated with an increased frequency of internal tandem duplication mutations within FMS-like tyrosine kinase-3 (FLT3) and a complex karyotype, while PTBP1 expression was not correlated with FAB classification, monosomal karyotype, isolated biallelic CCAAT/enhancer-binding protein α (CEBPA) mutation, or nucleophosmin 1 (NPM1) mutation in patients with AML. Moreover, PTBP1 expression was associated with a poorer prognosis according to risk stratification and a lower CR rate in AML patients. In addition, PTBP1 expression was positively correlated with the expression of the proliferation marker Ki-67 and negatively correlated with the expression of the apoptosis marker p53 in AML patients. Overall, PTBP1 is a viable biomarker that contributes to the risk prediction and the determination of potential drug targets for AML.","PeriodicalId":16112,"journal":{"name":"Journal of Investigative Medicine","volume":" ","pages":"891-899"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dual vs triple antithrombotic therapy in atrial fibrillation and acute coronary syndrome: An updated meta-analysis of randomized controlled trials. 快讯心房颤动和急性冠状动脉综合征的双重与三重抗栓疗法：随机对照试验的最新 Meta 分析。

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2024-12-01 Epub Date: 2024-08-28 DOI: 10.1177/10815589241270640

Enkhtsogt Sainbayar, Hoang Nhat Pham, April Olson, Ramzi Ibrahim, Harneet Grewal, Mohammed Salih, Mamas A Mamas, Kwan Lee

{"title":"Dual vs triple antithrombotic therapy in atrial fibrillation and acute coronary syndrome: An updated meta-analysis of randomized controlled trials.","authors":"Enkhtsogt Sainbayar, Hoang Nhat Pham, April Olson, Ramzi Ibrahim, Harneet Grewal, Mohammed Salih, Mamas A Mamas, Kwan Lee","doi":"10.1177/10815589241270640","DOIUrl":"10.1177/10815589241270640","url":null,"abstract":"Antithrombotic treatment in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) poses a dilemma. We compared outcomes of dual antithrombotic therapy (DAT) (direct oral anticoagulants (DOACs)/warfarin + antiplatelets) vs triple antithrombotic therapy (TAT) (DOACs/warfarin, aspirin, and P2Y12 inhibitor) in this population. Multiple databases were searched from inception to December 17, 2023 to identify randomized controlled trials (RCTs) comparing DAT vs TAT in patients with AF and ACS. Outcomes included major adverse cardiac events (MACE), bleeding events, stroke, stent thrombosis, and myocardial infarction (MI). Relative risk and 95% confidence intervals were estimated with a random-effects model using the inverse-variance technique. We assigned I2 > 50% as an indicator of statistical heterogeneity. p-Value <0.05 was considered significant. Ten RCTs comprising 6186 patients on TAT (female 26%, mean age 71 ± 9 years) and 6800 patients on DAT (female 27%, mean age 71 ± 9 years) were included. Patients receiving DAT experienced lower rates of bleeding events compared to those receiving TAT, with relative risks of 0.69 [0.55-0.87] (p < 0.001), 0.65 [0.40-1.06] (p = 0.09), and 0.62 [0.46-0.84] (p < 0.001) for TAT durations of 3, 6, and 12 months, respectively. No difference was seen in the occurrence of MACE, MI, stroke, or stent thrombosis between DAT and TAT across all three durations of TAT. This is the largest pooled analysis comparing TAT to DAT stratified by the duration of antithrombotic therapy. Our results revealed that DAT was associated with reduced bleeding risk despite no difference in other outcomes.","PeriodicalId":16112,"journal":{"name":"Journal of Investigative Medicine","volume":" ","pages":"956-960"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141875017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0